Product Information
ARNUITY ELLIPTA 50 MCG INH is a brand product labeled by GlaxoSmithKline LLC, priced at $6.6460 per EA under NDC 00173088810. Its NADAC has been published 381 times since Jun 19, 2019.
FDA first approved this application on Aug 20, 2014.
Strength
50 ug/1
Manufacturer
GlaxoSmithKline LLCNDC
00173088810
Classification
Brand
Dosage Form
POWDER
Route
RESPIRATORY (INHALATION)
Effective Date
9/23/2026
Active Ingredients
FLUTICASONE FUROATEApproval Type
New Drug (NDA)
FDA Application
NDA205625FDA Approved
8/20/2014
On Market Since
5/17/2018
Pharmacological Classes
Price Statistics
The NADAC for ARNUITY ELLIPTA 50 MCG INH has been published 381 times since Jun 19, 2019, and over the history we have for it it has risen 20.0%. The table below summarizes its recorded NADAC range and movement.
| Current price | $6.6460 per EA |
|---|---|
| All-time high | $6.7215 (Apr 10, 2024) |
| All-time low | $5.5399 (Jun 19, 2019) |
| 52-week high | $6.6546 |
| 52-week low | $6.6434 |
| Median price | $6.6434 |
| Average price | $6.2802 |
| Largest weekly change | +4.9% (Jul 13, 2022) |
| Weeks tracked | 381 |
| Tracking since | Jun 19, 2019 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 36% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
GlaxoSmithKline LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
fluticasone furoate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Corticosteroid class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ARNUITY ELLIPTA 50 MCG INH?
The current National Average Drug Acquisition Cost (NADAC) for ARNUITY ELLIPTA 50 MCG INH, manufactured by GlaxoSmithKline LLC, is $6.6460 per EA (NDC 00173088810), effective Sep 30, 2026.
How has the price of ARNUITY ELLIPTA 50 MCG INH changed over time?
Over the history we have for it, the NADAC for ARNUITY ELLIPTA 50 MCG INH has risen 20.0%. It has been tracked across 381 weekly CMS publications since Jun 19, 2019.
What are the highest and lowest recorded NADAC prices for ARNUITY ELLIPTA 50 MCG INH?
Since Jun 19, 2019, the NADAC for ARNUITY ELLIPTA 50 MCG INH has ranged from a low of $5.5399 (Jun 19, 2019) to a high of $6.7215 (Apr 10, 2024), with a median of $6.6434 per EA.
Are there cheaper alternatives to ARNUITY ELLIPTA 50 MCG INH?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, FLUTICASONE ELLIPTA 50 MCG INH, is $4.2206 per EA — about 36% below ARNUITY ELLIPTA 50 MCG INH.
Who manufactures ARNUITY ELLIPTA 50 MCG INH?
ARNUITY ELLIPTA 50 MCG INH (NDC 00173088810) is labeled by GlaxoSmithKline LLC, and CMS classifies it as a brand product.